1) Greinacher A, Farner B, Kroll H, et al:Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 94:132-135, 2005
2) Linkins LA, Dans AL, Moores LK, et al:Treatment and prevention of heparin-induced thrombocytopenia:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e495S-530S, 2012
3) 松尾武文,星野信広:血栓と循環の検査法 凝固線溶検査シリーズ ヘパリン起因性血小板減少症(HIT)の病因としてのヘパリン・PF4複合体抗体の検査(解説).血栓と循環16:246-250,2008
4) 宮田茂樹,前田琢磨:抗血栓療法と薬の使い方.ヘパリン起因性血小板減少症(HIT)に対する抗血栓療法.月刊薬事7:1089-1094,2012
5) 宮田茂樹:循環器疾患の早期発見の最前線.血栓性疾患.ヘパリン起因性血小板減少症(Heparin-induced thrombocytopenia:HIT).Modern Physician 26:825-826,2006
6) 日本整形外科学会:静脈血栓塞栓症予防ガイドライン.南江堂.pp10-23,2008
7) Warkentin TE, Greinacher A:Heparin-induced thrombocytopenia:recognition, treatment, and prevention:the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:311-337, 2004
8) Warkentin TE:INTERFACE.臨床.ヘパリン起因性血小板減少症(HIT)に対する診断と治療.International Review of Thrombosis 6:336-345,2011